- Home
- STSS vs ENTO Comparison
STSS vs ENTO Comparison
Compare STSS & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- ENTO
- Stock Information
- Founded
- STSS 2017
- ENTO 2014
- Country
- STSS United States
- ENTO United States
- Employees
- STSS N/A
- ENTO N/A
- Industry
- STSS Medical/Dental Instruments
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- ENTO Health Care
- Exchange
- STSS Nasdaq
- ENTO Nasdaq
- Market Cap
- STSS 3.0M
- ENTO 2.9M
- IPO Year
- STSS 2022
- ENTO 2016
- Fundamental
- Price
- STSS $0.32
- ENTO $0.59
- Analyst Decision
- STSS
- ENTO
- Analyst Count
- STSS 0
- ENTO 0
- Target Price
- STSS N/A
- ENTO N/A
- AVG Volume (30 Days)
- STSS 2.4M
- ENTO 72.4K
- Earning Date
- STSS 03-31-2025
- ENTO 11-13-2024
- Dividend Yield
- STSS N/A
- ENTO N/A
- EPS Growth
- STSS N/A
- ENTO N/A
- EPS
- STSS N/A
- ENTO N/A
- Revenue
- STSS N/A
- ENTO N/A
- Revenue This Year
- STSS N/A
- ENTO N/A
- Revenue Next Year
- STSS N/A
- ENTO N/A
- P/E Ratio
- STSS N/A
- ENTO N/A
- Revenue Growth
- STSS N/A
- ENTO N/A
- 52 Week Low
- STSS $0.30
- ENTO $0.19
- 52 Week High
- STSS $18.15
- ENTO $9.35
- Technical
- Relative Strength Index (RSI)
- STSS 12.70
- ENTO 56.47
- Support Level
- STSS $0.34
- ENTO $0.48
- Resistance Level
- STSS $0.42
- ENTO $0.63
- Average True Range (ATR)
- STSS 0.13
- ENTO 0.07
- MACD
- STSS -0.15
- ENTO 0.01
- Stochastic Oscillator
- STSS 1.12
- ENTO 86.74
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.